Citizens JMP lowered the firm’s price target on Quince Therapeutics (QNCX) to $8 from $9 and keeps an Outperform rating on the shares. The firm is impressed with management’s execution in completing enrollment for the pivotal NEAT trial, which is set up for success, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QNCX:
- Quince Therapeutics Reports Q2 2025 Financial Results
- Quince Therapeutics reports Q2 EPS (34c), consensus (23c)
- QNCX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quince Therapeutics initiated with an Outperform at Citizens JMP
- Quince Therapeutics files to sell 6.67M shares of common stock for holders